Amoy Diagnostics Co Ltd
300685
Company Profile
Business description
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Contact
39 Dingshan Road
Haicang District
Xiamen361027
CHNT: +86 5926806835
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
1,144
Stocks News & Analysis
stocks
Undervalued ASX share with plan to mitigate tariff risk
Shares have dropped 20% in the previous year due to concerns about tariffs.
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,298.00 | 24.00 | -0.26% |
| CAC 40 | 8,239.18 | 13.55 | 0.16% |
| DAX 40 | 24,308.78 | 68.89 | 0.28% |
| Dow JONES (US) | 47,544.59 | 337.47 | 0.71% |
| FTSE 100 | 9,653.82 | 8.20 | 0.09% |
| HKSE | 26,366.37 | 67.33 | -0.25% |
| NASDAQ | 23,637.46 | 432.59 | 1.86% |
| Nikkei 225 | 50,419.96 | 92.36 | -0.18% |
| NZX 50 Index | 13,393.98 | 2.39 | 0.02% |
| S&P 500 | 6,875.16 | 83.47 | 1.23% |
| S&P/ASX 200 | 9,016.30 | 12.50 | -0.14% |
| SSE Composite Index | 3,994.80 | 2.15 | -0.05% |